Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...
Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...
Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...
A clade is a group of viral strains that share a common ancestor. While traditional bird flu vaccines often only cover one clade at a time, Boehringer Ingelheim leveraged a technology called COBRA ...
Launching this month, Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well as for the prevention of Marek disease and infectious ...
Boehringer Ingelheim Pharmaceuticals, Inc. Welcomes Brian Hilberdink as President, U.S. Human Pharma
RIDGEFIELD, Conn., Feb. 20, 2025 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today the appointment of Brian Hilberdink as President, U.S ...
RIDGEFIELD, Conn. and INGELHEIM, Germany, Feb. 19, 2025 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback